Thank you.
I would like to move on to the folks representing Canada's research-based pharmaceutical companies and just ask a couple of questions.
In your first recommendation you state that Canada's intellectual property regime needs to be improved. You talk about the “effective right of appeal” and “an existing legal imbalance”.
Can you explain that for us?